Navigation Links
Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
Date:1/7/2008

MADISON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008, at the Westin St. Francis in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at 11:00 a.m. Eastern Time.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.metameetings.com/webcasts/jpmorgan/healthcare08 and to the public at http://www.questdiagnostics.com. In addition, the archived webcast will be available within 24 hours after the presentation and will remain available until February 7, 2008.

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.questdiagnostics.com.

The statements in this press release which are not historical facts or information may
'/>"/>

SOURCE Quest Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
(Date:6/18/2013)... (Monday, June 17, 2013) A million electric cars could ... the decade with the help of research by the United ... University of Waterloo. , Professor Zhongwei Chen is part of ... to develop non-precious materials to replace the expensive platinum catalysts ... the adoption of fuel cells in vehicles is the cost ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 (PRWEB) June 18, 2013 ... time and attendance system in North America, has ... shares employee data and payroll records between ExakTime’s ... Plus automates ExakTime software setup and keeps ... imports employee data from a business’ current payroll ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2
... Silence Therapeutics plc (London AIM:,SLN), a leading ... the successful opposition of a fundamental Alnylam,Pharmaceuticals, Inc. ... its entirety., The Opposition Division of the ... its decision to revoke European Patent EP 1,230 ...
... First-in-Man study success, Ovalum Ltd. launches a multicenter study using ... privately held Israeli medical device company, has announced today successful ... in the coronary arteries. , ... ...
... European Molecular Biology Laboratory (EMBL) discovered a new way to ... computational method that compares how similar the side effects of ... on the same target molecule. The study, published in ... drugs. , Similar drugs often share target proteins, modes of ...
Cached Biology Technology:Silence Therapeutics Announces Successful Opposition of Glover Patent 2Silence Therapeutics Announces Successful Opposition of Glover Patent 3Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire 2Teaching old drugs new tricks 2
(Date:6/18/2013)... a chemical modification of DNA and this modification ... DNA sequence. Until now, scientists believed that this ... genes. Today, a team of researchers from the ... Dermitzakis, Louis-Jeantet Professor at the Faculty of Medicine, ... and that DNA methylation may play both a ...
(Date:6/17/2013)... high levels of air pollution while pregnant were up to ... women who lived in areas with low pollution, according to ... It is the first large national study to examine links ... findings raise concerns since, depending on the pollutant, 20% to ... where risk of autism was elevated," said lead author Andrea ...
(Date:6/17/2013)... JOLLA, CA June 17, 2013 An international ... (TSRI), the Howard Hughes Medical Institute and Albert Einstein ... highly promising new anti-tuberculosis compound that attacks the tuberculosis ... represent an effort to help solve one of the ... TB and its dangerous drug-resistant strains," said Peter G. ...
Breaking Biology News(10 mins):The secret of DNA methylation 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... before it has a chance to take root and ... discoveries in cancer prevention. Leading experts from around the ... this expanding and promising new field, with the hope ... To help you take advantage of the meeting,s ...
... Caswell et al.report in the Journal of Cell ... prompt metastatic movement in tumor cells., On 2D surfaces, ... which link the cell to the extracellular matrix, are ... how has been unclear. Recent work has suggested that ...
... the current financial climate has taught us anything, it,s that ... It turns out this rule applies as much to our ... body deals in energy borrowed from muscle and given to ... in the body is under strict regulation to ensure that ...
Cached Biology News:Food for thought -- regulating energy supply to the brain during fasting 2Food for thought -- regulating energy supply to the brain during fasting 3
Plasmid expressing Zeocin resistance gene....
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... template is designed to allow neomycin/kanamycin ... The FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance ... for expression of kanamycin resistance in ... for expression of neomycin resistance in mammalian ...
Biology Products: